Vycor Medical Reports Significant Growth in Financial Results for Mid-2025

Vycor Medical, Inc. (OTCQB: VYCO) has released its financial results for the three and six months ended June 30, 2025, showcasing significant growth in both revenues and operating profits. The company, which operates through its Vycor Medical and NovaVision divisions, reported a 24% and 28% increase in revenues for the respective periods, primarily fueled by expansion in international markets.

The Vycor Medical division, known for its ViewSite™ Brain Access System (VBAS), saw revenues rise to $481,788 for the three months ended June 30, 2025, up from $387,249 in the same period in 2024. This growth is attributed to the company's strategic entry into new markets, including France and Spain, through distribution agreements. Additionally, the publication of two new clinical papers on VBAS during the quarter, bringing the total to 48 peer-reviewed studies, underscores the system's clinical advantages in neurosurgery.

NovaVision, Vycor's division focused on therapy programs for visual disorders post-stroke or brain injury, also made strides with the publication of a new study on its NeuroEyeCoach program. The study validated the program's effectiveness in both home-based and clinic-based settings, aligning with global healthcare trends towards digital and remote therapies.

Financially, Vycor reported a non-GAAP operating profit of $84,481 for the three months ended June 30, 2025, a substantial increase from $31,859 in 2024. For the six-month period, the non-GAAP operating profit reached $106,944, compared to $40,311 in the previous year. These figures highlight the company's improved operational efficiency and cost management.

The company's gross profit margin for 2025 stood at 83%, slightly lower than the 91% reported in 2024, due to validation and shipping costs associated with new production and changes in the geographical sales mix. Despite these challenges, Vycor's financial performance demonstrates robust growth and a strong position in the medical technology sector.

For more detailed financial information, including reconciliations of GAAP to non-GAAP measures, interested parties can refer to the company's official website. Vycor Medical's continued focus on innovation and market expansion signals promising prospects for the future of neurosurgical and vision rehabilitation therapies.